A randomired, double blind, parallel study wclc performed to compare the effects of nifedipine gastrointestinal therapeutic system (GITS) to hydrochlorothiazide ( HmZ) in the management of the elderly hypertensive. Eighteen patients, mean age 65 + 5 years, with Stage I-III diastolic hypertension (sitting diastolic BP between 90 and 115 mm Hg) were included in each treatient group. Following a 2 to 8 week placebo washout phase, patients received either nifedipine GITS or HCTZ and wem titrated over 5 weeks to achieve a goal diastolic blood pressure less than 90 mm Hg.
A randomired, double blind, parallel study wclc performed to compare the effects of nifedipine gastrointestinal therapeutic system (GITS) to hydrochlorothiazide ( HmZ) in the management of the elderly hypertensive. Eighteen patients, mean age 65 + 5 years, with Stage I-III diastolic hypertension (sitting diastolic BP between 90 and 115 mm Hg) were included in each treatient group. Following a 2 to 8 week placebo washout phase, patients received either nifedipine GITS or HCTZ and wem titrated over 5 weeks to achieve a goal diastolic blood pressure less than 90 mm Hg.
Patients were then cantinazd on medication during an 8 week maintenance phase. Treatment effect on systolic and diaskliz blood pressure was assessed. Serum ektrolytes, lipids, blood urea nitrogen, and cmatinine were measured beftire and after treatment. Posttreatment changes in renaI and cardiovascular function, as well as left ventricukr mass were evaluated.
The results showed +gnikant reductions in systolic and diastolic blood pressure with bGth drugs; no treatment difference was found, although goal blood pressure was achieved more rapidly with nifedipine GITS (28 u 34 days, P < .05). BUN was signi6canily increased only after diuretic therapy (P < .Ol) and serum potassium fell to a greater degree with HCTZ (0.3 mEq/L 'I) 0.1 mEq/L) than with nifedipine GITS. No statistically significant changes in left ventricular mass, ejection fraction, glomerular fileation rate, or renal blood flow were seen after therapy with either drug. However, the time to peak LV diastolic K!:'ng rate decreased with nifedipine GITS (197 to 164 msec) and increased with HCTZ (172 to 198 msec 1. This treatment difference approached statistical significance (P = ,071. Adverse side effects of treatmer t were reported by 50% of nifedipine GITS atients and 28% of patients treated with HCTZ. This tie&nent difference was not statistically significant.
We conclude that both nifedipine GITS and H-Z monotherapy provide significant blood pressure reduction in older hypertensives with Stage I-III diastolic hypertension. Both drugs are well tolerated with no significant adverse eh:ect on renal or cardiovascular function after short term therapy. -4m J Hypertens 1996;9:589-606 T he majority of drugs and drug classes approved for use as antihypertensives are effective as monotherapy fr,r hypertension. Diuretics, dnglotensin convertil+ enzyme (ACE) inhibitors, calcium entry blockers, and Q-and fi-adrenoreceptor blockers all reduce blood pressure (BP) without a substantial number uf ddvcrse reactions, and sn ail were recommended as initial (mono) therapy for hypertension by the Fifth Joint National Committee on the Detection, Evaluation and Treatment of High Blood Pressure (JNC V).' Of these, diuretics and P-adrenoreceptor blockers were designated as preferred because these two classes of drugs had been successful at reducing morbidity and mortality in hypertensives when compared to placebo or usual care in !ont+rm and large scale clinical trials.
To date four such clinical trials have shown that diuretics have kn paIiicularly effective in the elderly. Hydrochlorothiazide (HCTZ) and ChlorthaIidone as initial therapy, with or without potassium sparing diuretics, reduce both sys&!ic and diastolic BP with a seemingly acceptable number of side effects and, most importantly, also reduce the incidence cf stroker. roronary arter)-disease (CAD), congestive heart iaihrc (C'HF), and overall cardiovascular events in this age group? &cause of thr; firdings of thw trials, the Working Group on Hypertension in the Elderly of the hational High Blood Pressure Education Program recommended diuretics for initial therapy for treating hypertension in those over the age oi 60, unless there was a specific reason to favor another a;=enLh Adverse reactions, lack of efficacy, or better organ specific action would all be appropriate reasons to favor an alternative agent. P-Adrenoreceptor blockers were not recommen.+d by the Working Group because of the results of the Mtulical Research Council-Elderly Study that did not show benefit in reducing events when atenolol, the P-a3rcnareceptor blocker used, was compared to placebo .4
While highly effective and generally quite safe, diuretics may not zs yet be the pert'ect antihypertensive for all or even most of the elderI:.-For example, though generally well tolerated, in the European Working Party on Hypertension in ;hs Eld,nrly study IEWPHE 1, diminished renal function was reported in 44% of patients after the first year a4 adverse rretabolic effects were noi inhequent,','*" P3:.is5i~~ll s:lpplementation was often required to prevent hypokalemia and glucose intolerance was more cclmmon in the active than the placebo treated volunteers. HCTZ.9, 'u In both subgroups, and for the study cohort as a whole, the calcium entry b::lcker diltiazem reduced BP better and A;icv~d goal BP in more patients than did HCTZ. <.alcium entry b!xt~:~ may also be more effective than diuretics at improving diastolic dysfunction, a common cardiac abnormality in the elderly, and may do so without any significant risk of ~rolume depletion."-"
We felt that nifedipine GfTS (gastrointestinal thtlr+ peutic systemi might be a particularly safe and effective choice for the treatment of older patients with Stage I-111 diastolic hypertension (DBP 90 to 115 mn; Hg 1, This sustained release talc ium cn try blocker has been reported to reduce BP and improve ventricular function, "," while maintaining serum potassium levels and preserving renal function.""' The objective of this study was to compare the effects oi once daily monotherapy for hypertension, with either nifedipine GITS or HCTZ in a cohort of o!dcr pzticnts. WC hypthesized that !xth drugs would be effective in reducing BP', but that niftr'ipinc GlTS would be better tolerated, not reduce Sio;,d voiume, and have a more favorable impact on cardiac and renal function.
METHODS

Study aesign
The study was performed at tw;) sites, the Yale-New Haven Hospital and the West H;rven Vcterans Affairs Medical Center, by the same investigators. Data acquisition., subject recruitment, and data anakk FiotMols were identical &twwn institrj tions. This iouble-blind, parallel study was divided intil four pha%. After obtaining infiJrr.4 c'~nwn1, a pretreatment evaluation including a complete medical history and phvsical examination was performed (Phase 1, Quz!if$ng Pnase). Patients meeting study entrance criteria (see below) then enterzci a 2 to 8 week r!c:-eI~ washout period (Phase 2, PlacPbL: Treat*:?nt Phase). All antih,rperten$ve medications were wit'lhdd and patients were asked to rP:una for weekiv 37 and heart rate measur:*lne3+!: ~3!~~c~ze experie:rCe--valuation, and complirir:w chcc: i For patients rrat previously on antihyrd:r-:encive the-agy, Phase 2 was shortened to 2 wee! s. If at any time the diastolic BP exceeded 115 mm Hg, the pa tier: t wa.; dropped from the study. Patients were also required to have taken on average 805 to 120% of the? prescribed medication ( placebo) in order to proceed to Phase 3.
All patients successfully completing Phaw 1 and 2 underwent a series of baseline examinations including BP, heart rate, and weight determinations. Sitting and star ding bl,,4 pressures were recorded as the average of three indEpendent measurements taken 2 min apart.
The diastoIic component was defind as the press-.rp registered when Korotkoff sounds disappeared.
Laboratory Studies Blood work included complete blood count with differential and platelet count, scquential multiplier analyzer (SMA-18) with gluct~, cholesterol, triglyceride+, uric acid, blood urea nitrogen, and Lzatinine. A urinalysis and 12-lead electrocardiogram were obtained. Renal blood flow ( RBF 1 was measured with "'I-hippuran and the glomerular filtration rate (GtR) was rstimnttd by 'Ih"Tc-diethlycnctr~.minepentaacetic acid (DT'PA ) renoscintigraphy. Bid volume was &mat4
by "Cr isotope dilution ttrhnique. M-mode echocardiography was perfklrmed for meirsurement of left ventricular {LV) mass. Resting @cd radionuclide cineangiography was performed for measurement of LV systolic (ejection fraction, ejection rate) and diastolic (peak filling rate, time to peak filling rate) function.
Active Treatment
After completion of all baseline testing, patients were randomized by computer generated ctie to rtu-eive either niftriipine Gil3 (Prtxardia XL, Pfizer, New York, New York) or HC'TZ. Phase ,3 (Titration Phase) consisted of a variable S week perid that was &fintd by the time necessary for the patient to achieve goal diastolic BF. The goal was a sitfing djastolic BP on two consecutive visits of < 90 mm HP; or a reduction in diastolic BP 2 10 mm Hg, if baseline diastolic BP was between 90 and 99 mm Hg. Dosing for patients in the nifedipinc group bzgalb at 30 nqq daily and was adjusted by .70 mg increments at wmkly intervals to a maximum of 120 mg daily until goal BI' was achieved. Patients randomized to HCTZ were simiIarly titrated through a dose range of 12.5 to 50 mg daily. Al1 patients received a placebo preparation identical In aypnrarrcz tr) tilt2 ~!krHdti: studs; Jrtig si~bzh that they remained blinded to their treatment.
Patients who did not achieve goal BP al the maximum tolerated dose of either nifedigin-? -trli i-iCTZ at any visit were considered treatment failures and were withdrawn from the study. Patients with sitting diastolic BP < 90 mm Hg at only one of two tnai titration visits ?d not achieve goal, but were Icntinued into Phase 1 (Maintenance Phase). During Phase 4, patients were continued on their study medication for 8 weeks.
Patients were instructed to return at the end of the fourth week for BP measurement and possible dosL' adjustment. Complete laboratory tests, blood volume, renal blood flew, renal function, radionul-;ide cinezgiogrsphy, and echocardiography were repeated at the final visit.
Patient Selection Men and postmenopausal women aged 55 to I15 years with a measured or history of diastolic BP between 90 and 115 mm Hg were recruited for the study. Erclllsion criteria includtd: concomitant therapy with other z.;ltihyprtensive drugs, the expectat!rbn that 11 : patient could not be managed on single drug therapy, a history of myocardial infarction 11r celebrovascular accident within the 6 months prior to study entry, known hcpatic dysfunction or a *rum creatinine greater than 2.0 mg / dL. A history of congestive heart failure, uncontrolled arrhythmias, or heart block greater than first dt1greP also disqualified the patient from enrollment. We also excluded patients with gout, insulin-dependent diabetes, symptomatic orthostatic hypotensipn, or a history of significant gastrointestinal disorder idiverticulitis, partial or total gastrectomy, small bowel rryecticr., or chronic diarrhea 1. Volunteers who had been given an investigational drug within 1 month of study entry, used laxatilles on a chronic basis, or had showp previous intolerance to niftiipine, HCTZ, or sulfa preparations were excluded. Patients were not permitted to donate blood for 1 month prior to or during study.
Statistical Methods
V~iables Armlyzcd We analyzed demsraphic and basehne physical examination variables including age, race, sex, height, weight, duration of hypertension, and pria>r antihypertensivp medications. We used the average of sitting and standing BP and heart rate of the last Iwo placebo visits as a pretreatment ba*line to evaiua'2 the changes resulting from HCTZ or nifedipine C;lTs therapy. We also measured and cornpa& the duration of the titration and maintenance phases. For all other variables, baseline was t!tie last washout visit. We evaluated radionuclide cinea;lgiogram measurements (LV ejecticn fraction, peak diastolic filling rate, time to peak filiing rate, peak ejertion rate), RBF and GFR, blood vclume and red cell mass, and echocardiographic findings (LV mass and LV mz,,m index as grams /meters'). For BP and heart rate, change from baseline was compared to the end of titration, end of maintenance, and tu the final visit. For all other variables change from baseline was compared to the final visit.
We calculated the correlations of LV mass, LV mass index, RBF, and GFR with BP, heart rate, and ejection fraction. Changes in biochemical an;l hematol*sic measurements and the number and type of adverse reactions occurrir;g were recorded and compared.
Mcfh& of Analysis Race, sex, number of patients attaining the goal BP, and the incidence of adverse exycriences were analyzd using Fisher's exact test. Prior antihypertensive medications were analyzd using a x2 test. A t test was used for age, height, weight, duration of hypertension, duration of titration, and duration of maintenance. For the renal function and echocardiw gram variables, treatment comparisclr.5 were perfg,rmed using analysis 0: variance with the sitting systolic and dtastolic BP as covariates. Change from baseline was &ted using a t test on the least squares means. Correlalion5 were tested using a 2 test.
For all other numeric efficacy variables, treatment compztiiu>ns were performed using a hvo sample t test, and a one sample t t&t x's used for change f.rom bawline. Laboratory value and chang% frrim tl;l.qrline were anaIyzed using the Wilcoxon signed rank test.
ZESULTS Patient Demographics
Thirty-seven hypertensive patients entered the study. One patient withdrew fnjm the study during the placebo phase and did not receive study medication. The remaining 36 patients were included in the safety and efficacy ana!;rses. Eir,hteen patients were randomized to each study drug. Raxline demographics are shown in Table I . The mean ay,e of these groups did not differ (65 4 5 years, range 55 ta 74 years). Fifteen of 18 nifedipine and 16/ 18 HCT7. patients were men, reflecting the fact that more th.rn half of the study subjtrts were enrolls from the WA Haven Veterans Affairs Medical Center. Seventy-eight percent of the nifedipine patients (15/ 18) were white, compared to 67% (IL/181 of the HCTZ group. The mean duration of hyprtcnsion was 13 years in IX&I groups. The groups were comparable for height, weight, previous medications for hypertension, dnd concurrent illness45
Two patients randomized to nifedipine CITS withdrew from the study during the titration phase due to adverse side effects: one patient complained of epigastric pain, the other had lower extremity edema. Five patients randomized to HCTZ withdrew from tht study during the titration phase: four due to inadequate BP control, and one patient with epigastric pain.
Effect of Study Drt.gs nn tliaod Pressure L&ring :itration, average daily doses were S8 ? 18 mg for nifedipine GITS and 29 f 8 mg for HCTZ. The duration of the titration phase was significantly shorter for nifedipine GITS patients (28 dayE1, ils compared trr HCTZ patients (34 cays) (r (. OS). The goal BI' was achieved at two consl!cutive visits b\r lO/ 18 nifedipinc paricijts and ?/ 18 ECKZ patients (I' r NS).
Skteen of 18 nifedipine GlTS patients and 13/ 18 HCIZ patients continued to the maintenance phase. The ilverage daily doses werp 77 +-31 mg for nifcdipine GI'I5 and 40 T 14. rns for HC'I'% durmg maintpnancr The !inal average daily doses :*:pre $0 2 31 mg for nifedipine GITS and 42 2 13 mg for I-KTZ.
'Tal~lr 2 displays the mean BI' anil heart rate f(lr each trcatr.lent group at baseline 2nd at thtm final visit. No stntist.cally signifkant truatmeili differrnc:trs wcrc found wtween the two goups at baseline, titration, or ai the end of the maintenance phase. Significant reductions in systolic and diastolic BP w+rri* fnl~nd aftrr treatment with both study drqp whet? w;!hin group hast!-line WAS compdreci with titration, end of mainknancc, and firlal visit measurements (Figure 1 ). No statistically s;g,nifictlpt changes were found for heart rate either within or between treatmtnt groups. Effect on Left Ventricular Mass apd Function 1,V mass and mass index were cornpar:& for both study groups at baseline and afkr treat1.it:r.t. No significant treafrnent effect was observed for either drug. Ekeline and posttreatment mcasurcmonts of LV systolic (ejection fraction, peak ejection rate) an; diastolic (peak filling rate, tirnr> !I_, peak filling 1 performance wcr~ comparable. No statistically significant treatment differences were fouird al baseline. psttreatment, or as; a change from bawllnc* (Table 3 1, HoweK*er. the average time to peak filling rate for nifedipinc CHITS patients &cretisild by :y;, (from 197 to 16-i mwci, ,i~:d for IICTZ paticr.ts incrtawd, by 1s'; (from I72 to 19Y msec). Thk treatment difference approached significilnw (P = 471, (Table 4) . Nifedipine GITS Treatment Effect an Sgrum Chemistries Both blood urea nitrogen (SUN) and uric acid were sigijificantly increased with HCTZ therapy. BUN decreased with nifedipine GITS treatment; uric acid levels were minirnally increased. These treatment differences were statistically significant (Table 5 ). The posttreatment chlo ride leve! was significantly lower 2nd calcium significantly higher for HCTZ compared to nifedipine GITS. Posttreatment HDL levels hvere significantly higher fcr HCTZ (50.6 mg/dL) compared to nifedipine GITS (42.2 mg / dL). Triglyce rides and LDL cholesterol levels were comparable at base!ine and after treatment.
No other statistically significant treatment differences beere found. Serum potassium levels feIl, however, to a gr:Jter extent with HCT1, (0.3 mEq/L) than with nif&rdipine GJTS IO.1 mEq /L) therapy. This difference approachid statistical significance (P = .07). Fasting serum glucose levels were comparable between treatment groups. DISCUSSION Effect on Rena: Blood Flow and Function No statistically signi%mt treatment differences or changes from Recent data from the third National Health and Nutribaseline GFR were found with either nifedipine GlTS tion Survey (;NHANES III) has estimated that 44% of or HCTZ. Baseline GFR was 10'1 -): 32 mL/min for the niftiipine group 1' 102 + 29 mL/min for the IKTZ group. After treatment, CER was 102 5 24 mL /min for nifedipine subjects and 114 5 3t mL/min for HCTZ. subjects (P = NSj. Renal blo& Bow was also unaffected by antihypertensive drug therapy. Mean renal biood fiow fur the nifediyint; group was 237 X: ,'min ,' m2 at baseline and 239 ml /nLin /mz after treatment. For ihe HCTX group, renal bid flow was calculated to be 232 ml /min /m2 at baseline and 254 ml /min /m' after treatment (P = NS).
Effect on Blood Volur;re I3lrxd volume and red cell mass were comparable between treatment groups. No significicnnt treatment differences were found at baseLine, after treatment, or as a change from baseline. Mean B 0 bid volume and red ccl! mass for the nifedipine E --5 group were 38 -+ 25 mL/kg and 24 ? 7 mL/kg at baseline, and 37 + 19 mL / kg and 22 2 3 mL i kg after box, mainlenancc phase; chedered 60x, fiwl visif. 
Americans aged 50 to 59 are h!:pertcns;ve, defined as a qs;oIi; BP of 140 mm Hg or greater or a diastolic BP of 90 mm Hg or greater or taking antihypertensive medication.'*'
The majority of Ihose aged 60 to 69 (54% ) and about 2 / 3 cf Ameri$qs 7U years of age or more hdvr high blood pressure. i'he impact of hypertension as a risk factor for a!l-cause mortality, and especially for cardiovascular ;Ind renal disease is weii established and contributes significantly to the increased rate of these conditions notable in ollr oldest citizens."
In view of the contributions made by hypertension to morbidity and mortality in the elderly, it IS particularly gratifying that the benefit of treating Ggh blood p:es;ure and reducing the associated clinicsf consequences has now been so unequivocaI1y demonstrated in this population.'"' Though thiazide and thiazide-like diuretics can be given much of the credit for our success, the potentially adverse biochemical changes seen \<rith full doss therapy and the lack of efficacy in a substantial number of elderly patients make it imperative that we continue to search for alternatives that work as well or bcttc: in the c!&x!y, svherc 2 x!!-!sensus cnmn?!!l~~e suggested that thiazides are the most appropriate choice for initial khcrapy.." Whether we sh~~ui,i 22; cificdly choose certain drugs and avoid others to treal hypertension because of organ specific effects or comorbid conditions, such as diabetes mellitus or diastolic dysfunction, or pick the same drug for aI1 patients who don't have definite contraindications, rem;llns ho!+ debated and unrcsr tlved ,lh This issue is rsr!icularly pertinent in the e!derIv who rarely arc free oi 5. ild organ damage, como*kAity, w other cardiovascular r:sk factors.
C,:lcium entrv blockers, particularly dihydropyridiners w'lich do nr;t increase th;g risk of high degree atrio\renfrixlar block, bradycardid, or systolic dysfunci!on fur which the elderly might be at p~rtic~llar risk, s-m to bc an appropriate alternative tc; thiaxides. ?&fedipine was the first reprcscn,:ative ,>f this class of antihvpertensives a>-ailable in the L;niterl S;ates. -45 soon as a well tolerated once-a-day preparntion (nifcdipine CIZ? became al-ailable, it rapidly became one of the most widely used ai'tihyper&nsivtts in this country. Nifed lpinc CITS, an osmo?icalIy J liv.;ClI
ii-:Cti.li-CUIC,UL,I LLIE~C~~UII~~L, i;X vides significant BP reduction." " A recently cornpItted large clinical trial conftrmed that nifdipine GlTS significantIp decreased BP in both elrlerl! and noneldcrly patients with mild to moderate hypl:rtrnsion after-12 weeks of therap!-. 10 this and other >tud-ies, there were no adverse effects of therapy on strum Iipids or electrolytes, serum glucose levels, BUN, or creatinine."~'h" Our study extends earlier sirrilar findings L\'ith di\wse ccrkMs of younger hypertensive patients.i"3 ive focused on the eld&ly, evaluated blood volume changes with therapy alld used mjophisti<atd metho& to measurer s?cific functioning of the heart and kiJney, i\rgans lvhich oiten funGi(Jn at the margins of normal in this age group. We ;JSO paid parlicular attention to the metabolic effect; of borh drugs, since dilarotics may be less useful in these individuals if the frequency or se\'eritv of such amlverse reactions puts the patients treated at any substantial additional risk, either immediately, or in the near or distant future. The number of patients included in our study was relatively small. HOWC~C;~ because rntxe substantial differences are reqcired for small stucies to reach a level of significance, these differences may be more important compared to differences detected in a larger study. "GGUP of the small size of our study, we felt that it was important to exarzine the data for patterns of difference, as well as fol statistically significant variations.
The resuits of thi.:, data analysis are described below.
Blood Pressure Significant reductions in systolic and diastolic Bl' were achrevecl with Mth drugs and no treatment difference was found. Mean standing and sitting BP decreas4 by 2t/ 13 and 15 / 13 mm Hg with nifedipine GlTS and 14/10 and 13110 mm Hg with HCIT. respectively. Resting heart rate was unchanged aiter treatment with either drug. Goal BP was attained more rapidly with the <aXurn antagonist, which may simply be a result of the rapid tiitration performed arrd does not necessarily confer a significant clinical advantage to the calcium en!ry blocker.
Metabolic Dilferences Our results showed very little metabolic difference between HCTZ and nifedipine GlTS although some of our concerns about using thiazides were confirmed. We found that uric acid and BUN incread with HCTZ and decreased with nifedipine therapy, and that these treatment differences were statistically, though not clinically, significant. A moderate decrease in serum potassium with HCTZ was noted, as would be expected. Potassium and uric acid levels showed little change after nifedipine Gm ddmin&ra-tion. Neither HCTZ nor nifedipine GITS caused signi& cant changes in scI"um 1ipic.s. The adverse changes in tipid levels that have hpen ar;striaM with diuretic therdpy irr the pastL' were not observea in our short term study. We also found that serum glucose levels wzre comparable before and after treatment with either drug.
Cardiac Measure
Nifedipine CXTS has been associated with improved LV function'-'*!"" and decread id;' ,T;r$s. I I.2627 Sh<ut-t<:nr! Cirrapy i3 reportd tcr ir,-crease LV stroke v<;!ame, cardiac output, 2nd peak ejection rate. with treatwEnt of rnc1r.z than 1 year, systolic parameters of LV furaction returned to baseiirie !pvels, hllk --. ? positive effect on diastolic performance was noted, with a decreased time to peak filling rate and an increased early diastolic filling fraction." Our data showed no statistically significant changes in LV systolic function, as judged by ejection fraction, or peak filling rate (a measure of diastolic function) after 8 weeks of maintenance therapy with r,ifedipine GITS or HCTZ. However, with nifedipine GUS rherapy the time to peak filling rate, another index of diastolic function, decreased by 17% compared to pretreatment baseline, and the peak ejection r;rte improved from 2.71 mL/sec to 3.05 FT. /XC, 2 13% ir,crcaz ;;*ith I-ICX! therapy the time to peak filling rate was prolonged by zpproximateIy 15% and the ejection rate shrlla&. no cbz,nge. These difference were not quite statistically significant (P = -071, but certainly suggest a potentially important effect considering the small sample size evaluated.
Extended treatment with nifedipine GTE yields sitinificant LV mass regression, as does treatment with most antihypertensives. 2')11 Phillips et al reported a 19% reduction in LV mass index after 6 months of therapy for severe hypertension.
The iitlllts btzk~rr dnC1 dfttar tr&ment. Whrn compared t 1 younK:rr men and wc>n~r*q, clderlv hypcrtr*nsivc patients' mav hnvc lower blood ~1l~mes.l"~" Thcstj p,l. tients are-thus at poten in1 risk for the de\-elnpmc~~t of orthostatic hypcrtensior when treated x4th drugs that cause voltimc dupletio.1, such as diuretics. We iuund no significant change ir blocKJ virlume or red cell m1>5s with eithx HCTZ or nifcrlipir.e GlJ'S.
Adverse Experiences 4dvcrs;c eif~ts 0i trr-.;ltn\cnt were reported by ? larg :r nurntxr of nifedipine CATS patients !50%) than oi HCT% patients (34% 1, This trcn+-ment difference did not reach stalistica1 sig:njhc,n~-,, and the incidence of particular ad\*ersc expricncus di:.l not vary between trc:atment graup~;. Despite the rAtimely ininor Gilt: ~ffcct:; r>F::rt&, both iiru~:s were GUIera& well tolerated by patients r)vtr the approsimate 13 week (titration plus maintenance) irerl tment period.
SUMMARY AND CONCLUSIONS
In summary, we foul-~ a th?t daily monotherapy with either nifedipino GITS or HCTZ produced signiiiix,: BP reduction in a cchort of elderly hypertensive patieI[ts with Stage I-III diastolic hypr .trnG~'~~ !!r>th drugs were well tolerated with no signiiirant adverstl effect on renal or cardiovascular function nftcr short term treatment. Serum chcmistqr profiles were somewhat more favor;lble after nifcdipine GIJ3 administration; howevtf, ilo othur s!atistirailv significant trtiatment diiferrnce ~~1s imnd. We conclude that nifedipine GlTS may be as eficctivc ns HCITT: for Rl' control in the elderly, and ihat treatment iuith !his calcium channel blocker may be Freferrt4 f(,r pticntr with ctlt'laitl colnylic;~tiuii5 oi hvp43t<nsic:n. I?'2 i'2n-not judge with currently a\railab!e dnt,~, ivhethcr nifcdipine GUS or any calcium channel Mocker Gl be as effective as thin&de and thiazide-like diuretics at reducing morbidity and mortality in hyprrtensives. elderly or otherwiw. Since these agents are particularly effective and well tolerated antihyprtensives in
